LEO Pharma Inc. Hosts TRH the Crown Prince and Crown Princess at U.S./Danish “Building Bridges”/ Skin Cancer Awareness Event

Company to promote skin cancer awareness via panel discussion, free cancer screening and donation

Parsippany, NJ – October 11, 2011 – LEO Pharma Inc., the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care, will co-host an event with the Danish Consulate General of Denmark in New York, entitled “Building Bridges” on October 21, 2011. The event is designed to highlight awareness and prevention of skin cancer as well as U.S.-Danish business relations. Honorary guests include His Royal Highness the Crown Prince of Denmark and Her Royal Highness the Crown Princess of Denmark. The event also celebrates the expansion of the LEO Pharma Inc. U.S. offices in Parsippany, New Jersey.

Event highlights include:

- A program highlighting the importance of skin cancer awareness and prevention including remarks from HRH the Crown Princess of Denmark, who is in her fifth year as patron of the Danish Cancer Society
- A panel discussion on the state of skin cancer globally and in the U.S., particularly actinic keratosis and squamous cell carcinoma, including David E. Cohen, MD, Vice Chairman for Clinical Affairs Department of Dermatology at New York University School of Medicine, and Dr. Christina Tan, the Acting Deputy Commissioner of the Public Health Branch in New Jersey’s Department of Health and Senior Services
- The presentation of a donation by LEO Pharma Inc. to the Skin Cancer Foundation
- Free skin cancer screenings open to the public in the surrounding community
- LEO Pharma Inc. U.S. headquarters ribbon-cutting ceremony

According to the Skin Cancer Foundation, skin cancer is the most common form of cancer in the United States with more than 3.5 million skin cancers in over two million people diagnosed annually. One in five Americans will develop skin cancer in the course of a lifetime. Actinic keratosis is the most common precancer with more than 10 million Americans affected. More than 700,000 new cases of squamous cell carcinoma are diagnosed every year.

“LEO Pharma is committed to furthering research within dermatology and to helping patients achieve healthy skin,” said John Koconis, President and Chief Executive Officer at LEO Pharma Inc. “To mark the expansion of the LEO Pharma Inc. U.S. offices in a meaningful way we chose to highlight skin cancer prevention as we aim to strengthen the bridge between those suffering with skin cancer and effective treatment. Also, in receiving such distinguished Danish guests -- in particular the Crown Prince and the Crown Princess of Denmark -- we honor both our company’s Danish heritage and the strong ties between our two great nations, as exemplified in part by our physical expansion here in the U.S.”

“Skin cancer and skin diseases are a common challenge for Denmark and the U.S.,” says Deputy Consul General in New York, Thomas Rizk. “The Consulate General of Denmark praises LEO Pharma’s efforts to prevent and treat skin cancer as well as their efforts in bringing these solutions to the U.S. in order to meet the continuing challenge of fighting this disease.”
The event will be held at 12:00 p.m. at LEO Pharma Inc. U.S. headquarters located at One Sylvan Way, Parsippany, New Jersey. For more information contact Jean Wayman at (973) 637-1608.

About LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more than 100 years of history as an independent, research-based specialty pharmaceutical company.

LEO Pharma A/S, makers of the Taclonex® brand of products, is wholly owned by the LEO Foundation. The company is developing a number of new products, including treatments for the skin disorders actinic keratosis and eczema.

To learn more about LEO Pharma Inc., visit www.leo-pharma.us.